Brintellix (Major Depressive Disorder) Market Research & Emerging Trends Report to 2023

Submitted by: Submitted by

Views: 10

Words: 941

Pages: 4

Category: Business and Industry

Date Submitted: 03/31/2016 11:14 PM

Report This Essay

Brintellix (Major Depressive Disorder) Market Size, Share, Trends, Company

Profiles, Demand, Insights, Analysis, Research, Report, Opportunities,

Segmentation and Forecast To 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide.

The MDD market is a crowded and competitive market, with more than 30 marketed products

available for the treatment of patients with MDD. The depression market is about to enter a

dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's

Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal

antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of

seven promising late-stage pipeline products into the market during the forecast period, from

2013 to 2023.

Brintellix (vortioxetine) is a multimodal antidepressant that is indicated for the treatment of

MDD and was co-developed by Lundbeck and Takeda. It gained FDA approval in October 2013

and EMA approval in December 2013. Brintellix launched in the US market in January 2014 and

its launch in European markets is expected during the second half of 2014 (Lundbeck, press

release, December 27, 2013).

Read Complete Report with TOC: http://www.radiantinsights.com/research/brintellixmajor-depressive-disorder-forecast-and-market-analysis-to-2023

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms,

diagnosis, pathology and treatment guidelines as well as an overview on the competitive

landscape.

- Detailed information on Brintellix including product description, safety and efficacy profiles as

well as a SWOT analysis.

- Sales forecast for Brintellix for the top eight countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and

Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a...